GlassScriptPhysician profile
Susan J Hines
NPI 1619947215
$570.65
in general payments reported to CMS, 2019-2025
17 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.70 · 2021: $235 · 2022: $33.27 · 2024: $31.35 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $72.41 | 2021-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $67.15 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $51.18 | 2021 | |
| Abbvie INC. | $50.10 | 2021-2025 | |
| Lilly USA, LLC | $44.81 | 2021 | |
| Amgen INC. | $37.36 | 2020-2021 | |
| Celgene Corporation | $34.10 | 2025 | Reblozyl |
| Janssen Biotech, INC. | $32.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.35 | 2024 | |
| Gilead Sciences, INC. | $29.40 | 2021-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $25.14 | 2025 | |
| Eisai INC. | $21.52 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.04 | 2020 | |
| Array Biopharma INC | $20.73 | 2025 | Mektovi, Braftovi, Tukysa |
| Morphosys, US INC. | $20.17 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $11.93 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.